Neurocrine Biosciences, Inc. (NBIX) Q1 2023 Earnings Results

Neurocrine Biosciences Misses on EPS — Stock Down 4.67%

Neurocrine Biosciences reported a significant loss in EPS, which contributed to a 4.67% drop in stock price following the earnings announcement. The lack of revenue data and guidance adds uncertainty about the company's financial outlook. Investors may be concerned about the company's ability to manage costs and adapt to market conditions in the near future.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.51	N/A	-298.44%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the difficulties faced during the quarter. They are prioritizing cost management and operational efficiency as they navigate the current market challenges.

Management expressed concerns about ongoing challenges in the market.

They noted that they are focusing on cost management and operational efficiency.

There was an emphasis on the need for strategic adjustments moving forward.

Neurocrine Biosciences Misses on EPS — Stock Down 4.67%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Misses on EPS — Stock Down 4.67%

Key numbers

Management commentary